The drug stent is still safe and effective
Release date: 2008-03-24
Drug stents continue to be a safe and effective treatment option for patients with coronary artery disease. During the China Interventional Cardiology Conference, held on March 20th and organized by the Chinese Medical Association and the American Congress of Cardiovascular Therapy, along with the Paris Revascularization Conference, experts emphasized this point. Gao Runlin, President of the Conference and an academician of the Chinese Medical Association’s Cardiovascular Disease Branch, along with European expert Eric, stated that drug-coated stents remain a reliable choice. The overall risk of thrombosis is not significantly higher than that of bare metal stents. However, patients who are unable to follow long-term dual antiplatelet therapy should consider using bare stents instead.
Gao Runlin highlighted that after receiving a drug stent, patients must take dual antiplatelet medications—specifically aspirin and clopidogrel—for at least 12 months. In cases involving complex lesions or special patient conditions, the duration may need to be extended. For those undergoing non-cardiac surgery who must stop clopidogrel, it is recommended to continue with aspirin and resume clopidogrel as soon as possible to reduce the risk of stent thrombosis. This approach has become widely accepted as a standard practice in preventing such complications.
The issue of drug stents came under scrutiny in 2006 during the World Congress of Cardiology, when some researchers raised concerns about potential late thrombosis and increased mortality. This sparked a heated debate over their safety. Due to public concern, some patients became anxious, and even doctors felt uncertain. However, in 2007, a series of randomized clinical trials showed that drug stents were just as safe as bare stents. There was no significant difference in mortality or heart attack rates between the two types. While there was a slight increase in late thrombosis (about 0.2% to 0.5% per year) after one year in patients with drug stents, the benefits in reducing restenosis and the need for revascularization were substantial. Therefore, the risk of late thrombosis did not outweigh the advantages of drug stents.
Gao Runlin also mentioned that ongoing research aims to develop even better drug stents. Scientists are focusing on two main areas: improving drug coatings and enhancing the polymer materials used to deliver the drugs. New biodegradable polymers and scaffolds are currently in development, with some already entering clinical trials. These innovations could further improve the safety and effectiveness of stent technology in the future.
Source: Shanghai Medical Device Industry Association
Antiparasitic Veterinary Drug refer to a class of drugs used to suppress, kill or expel parasites inside and outside animals.We are focuses on Anthelminitic ,Veterinary Drug Apis products-APIs for Veterinary Use include Albendazole ,Albendazole Sulfoxide ,Albendazole Sulphoxide HCL,Closantel Base ,Closantel Sodium Diclazuril,Eprinomectin, Febantel, Fenbendazole Flubendazole,Levamisole Base,Levamisole, Levamisole Phosphate, Luxalbendazole, Mebendazole, Niclosamide, Oxfendazole,Oxibendazole,Oxibendazole Hcl
Oxyclozanide,Rafoxanide, Tetramisole HCL, Thiabendazole, Triclabendazole,Dimetridazole
Professional Antiparasitic Veterinary Drug manufacturer is located in China, including Veterinary Drug Apis,Bulk Drug Dimetridazole,Raw Material Medicine Powder, etc.The standards comply with BP/USP/CP/EP,we can provide samples and COA for test ,also customized is no problem!Of course, anti-parasitic veterinary drug apis are more effective if they can be used in combination,like The combination of Veterinary APIs albendazole and ivermectin is the best partner for insect repellent!
api veterinary,Antiparasitic Drug,antiparasitic powder,antiparasitic medicine
NANYANG CHENGPENG PHARMACEUTICAL CO.,LTD , https://www.chppharm.com